{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:05:10Z","timestamp":1747713910951,"version":"3.40.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00885-4","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:34:52Z","timestamp":1747658092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis"],"prefix":"10.1186","volume":"26","author":[{"given":"Min","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"885_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D, Axial spondyloarthritis. Lancet. 2017;390:73\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(16)31591-4.","journal-title":"Lancet"},{"key":"885_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrrheum.2017.56","volume":"13","author":"V Ranganathan","year":"2017","unstructured":"Ranganathan V, Gracey E, Brown MA, Inman RD, Haroon N. Pathogenesis of ankylosing spondylitis - recent advances and future directions. Nat Rev Rheumatol. 2017;13:359\u201367. https:\/\/doi.org\/10.1038\/nrrheum.2017.56.","journal-title":"Nat Rev Rheumatol"},{"key":"885_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13933","volume":"1442","author":"M Lata","year":"2019","unstructured":"Lata M, Hettinghouse AS, Liu CJ. Targeting tumor necrosis factor receptors in ankylosing spondylitis. Ann N Y Acad Sci. 2019;1442:5\u201316. https:\/\/doi.org\/10.1111\/nyas.13933.","journal-title":"Ann N Y Acad Sci"},{"key":"885_CR4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, et al. 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770.","journal-title":"Ann Rheum Dis"},{"key":"885_CR5","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, et al. 2019 Update of the American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71:1599\u2013613. https:\/\/doi.org\/10.1002\/art.41042.","journal-title":"Arthritis Rheumatol"},{"key":"885_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3899\/jrheum.150721","volume":"43","author":"FP Kroon","year":"2016","unstructured":"Kroon FP, van der Burg LR, Ramiro S, Landew\u00e9 RB, Buchbinder R, Falzon L, van der Heijde D. Nonsteroidal antiinflammatory drugs for axial spondyloarthritis: A Cochrane review. J Rheumatol. 2016;43:607\u201317. https:\/\/doi.org\/10.3899\/jrheum.150721.","journal-title":"J Rheumatol"},{"key":"885_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.2005.041129","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006;65:423\u201332. https:\/\/doi.org\/10.1136\/ard.2005.041129.","journal-title":"Ann Rheum Dis"},{"key":"885_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/13543784.2021.2010187","volume":"30","author":"L Garcia-Montoya","year":"2021","unstructured":"Garcia-Montoya L, Emery P. Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. Expert Opin Investig Drugs. 2021;30:1109\u201324. https:\/\/doi.org\/10.1080\/13543784.2021.2010187.","journal-title":"Expert Opin Investig Drugs"},{"key":"885_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonz\u00e1lez-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11\u201334. https:\/\/doi.org\/10.1080\/14740338.2016.1240783.","journal-title":"Expert Opin Drug Saf"},{"key":"885_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, J\u00e4rvinen P, Sanchez-Burson J, Gaffney K, Lee EB, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: Sixteen-week results from a phase iii randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71:599\u2013611. https:\/\/doi.org\/10.1002\/art.40753.","journal-title":"Arthritis Rheumatol"},{"key":"885_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017;76:571\u201392. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210023.","journal-title":"Ann Rheum Dis"},{"key":"885_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80:71\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218398.","journal-title":"Ann Rheum Dis"},{"key":"885_CR13","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Harigai M, Genovese MC, Lindsey S, Takeuchi T, Fleischmann R, Bradley JD, Byers NL, Hyslop DL, Issa M, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020;79:1290\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216852.","journal-title":"Ann Rheum Dis"},{"key":"885_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21:89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2.","journal-title":"Arthritis Res Ther"},{"key":"885_CR15","first-page":"5237","volume":"71","author":"HM Lund","year":"2019","unstructured":"Lund HM, Haavardsholm EA, Rudin A. A multicenter randomized study in early rheumatoid arthritis to compare active conventional therapy versus three biological treatments: 24 week efficacy and safety results of the NORD-STAR trial. Arthritis Rheumatol. 2019;71:5237\u201340. S10(Abstract L09).","journal-title":"Arthritis Rheumatol"},{"key":"885_CR16","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, Kremer J, Greenberg J, Malley W, Onofrei A, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79:1400\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216761.","journal-title":"Ann Rheum Dis"},{"key":"885_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.semarthrit.2018.10.019","volume":"48","author":"X Baraliakos","year":"2019","unstructured":"Baraliakos X, Szumski A, Koenig AS, Jones H. The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. Semin Arthritis Rheum. 2019;48:997\u20131004. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.10.019.","journal-title":"Semin Arthritis Rheum"},{"key":"885_CR18","doi-asserted-by":"publisher","first-page":"1759720x2093427","DOI":"10.1177\/1759720x20934277","volume":"12","author":"M Lorenzin","year":"2020","unstructured":"Lorenzin M, Ometto F, Ortolan A, Felicetti M, Favero M, Doria A, Ramonda R. An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Ther Adv Musculoskelet Dis. 2020;12:1759720x20934277. https:\/\/doi.org\/10.1177\/1759720x20934277.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"885_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","volume":"74","author":"D Wendling","year":"2007","unstructured":"Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74:304\u20135. https:\/\/doi.org\/10.1016\/j.jbspin.2006.11.005.","journal-title":"Joint Bone Spine"},{"key":"885_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","volume":"30","author":"Y Mei","year":"2011","unstructured":"Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30:269\u201373. https:\/\/doi.org\/10.1007\/s10067-010-1647-4.","journal-title":"Clin Rheumatol"},{"key":"885_CR21","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","volume":"75","author":"E Gracey","year":"2016","unstructured":"Gracey E, Qaiyum Z, Almaghlouth I, Lawson D, Karki S, Avvaru N, Zhang Z, Yao Y, Ranganathan V, Baglaenko Y, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 2016;75:2124\u201332. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208902.","journal-title":"Ann Rheum Dis"},{"key":"885_CR22","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","volume":"74","author":"F Ciccia","year":"2015","unstructured":"Ciccia F, Guggino G, Rizzo A, Saieva L, Peralta S, Giardina A, Cannizzaro A, Sireci G, De Leo G, Alessandro R, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:1739\u201347. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206323.","journal-title":"Ann Rheum Dis"},{"key":"885_CR23","doi-asserted-by":"publisher","first-page":"155645","DOI":"10.1016\/j.cyto.2021.155645","volume":"146","author":"Y Kaneko","year":"2021","unstructured":"Kaneko Y, Takeuchi T. An update on the pathogenic role of IL-6 in rheumatic diseases. Cytokine. 2021;146:155645. https:\/\/doi.org\/10.1016\/j.cyto.2021.155645.","journal-title":"Cytokine"},{"key":"885_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/cei.12670","volume":"183","author":"H Jethwa","year":"2016","unstructured":"Jethwa H, Bowness P. The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. Clin Exp Immunol. 2016;183:30\u20136. https:\/\/doi.org\/10.1111\/cei.12670.","journal-title":"Clin Exp Immunol"},{"key":"885_CR25","doi-asserted-by":"publisher","first-page":"794054","DOI":"10.3389\/fphar.2021.794054","volume":"12","author":"M Wu","year":"2021","unstructured":"Wu M, Zhang H, Li Q, Chen H, Fang M, Yang L, Ding Y. Pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of the qx002n anti-il-17 monoclonal antibody: A phase i, randomized, double-blind, single ascending dose study in healthy Chinese volunteers. Front Pharmacol. 2021;12:794054. https:\/\/doi.org\/10.3389\/fphar.2021.794054.","journal-title":"Front Pharmacol"},{"key":"885_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138. https:\/\/doi.org\/10.1002\/art.1780270401.","journal-title":"Arthritis Rheum"},{"key":"885_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","volume":"17","author":"R Landew\u00e9","year":"2015","unstructured":"Landew\u00e9 R, van Tubergen A. Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep. 2015;17:47. https:\/\/doi.org\/10.1007\/s11926-015-0522-3.","journal-title":"Curr Rheumatol Rep"},{"key":"885_CR28","doi-asserted-by":"publisher","first-page":"637829","DOI":"10.3389\/fimmu.2021.637829","volume":"12","author":"C Schinocca","year":"2021","unstructured":"Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, Guggino G. Role of the il-23\/il-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:637829. https:\/\/doi.org\/10.3389\/fimmu.2021.637829.","journal-title":"Front Immunol"},{"key":"885_CR29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/s0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landew\u00e9 R, Wordsworth P, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705\u201313. https:\/\/doi.org\/10.1016\/s0140-6736(13)61134-4.","journal-title":"Lancet"},{"key":"885_CR30","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/s0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landew\u00e9 R, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392:2441\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(18)31946-9.","journal-title":"Lancet"},{"key":"885_CR31","unstructured":"European medicines agency [internet]. secukinumab. approval available from: https:\/\/www.ema.europa.eu\/contact. 2015."},{"key":"885_CR32","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/00124743-199904000-00014","volume":"26","author":"A Spoorenberg","year":"1999","unstructured":"Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, van der Tempel H, van der Linden S. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999;26:980\u20134. https:\/\/doi.org\/10.1097\/00124743-199904000-00014.","journal-title":"J Rheumatol"},{"key":"885_CR33","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.3899\/jrheum.130588","volume":"40","author":"D Wallis","year":"2013","unstructured":"Wallis D, Haroon N, Ayearst R, Carty A, Inman RD. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? J Rheumatol. 2013;40:2038\u201341. https:\/\/doi.org\/10.3899\/jrheum.130588.","journal-title":"J Rheumatol"},{"key":"885_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-020-00924-5","volume":"22","author":"D Poddubnyy","year":"2020","unstructured":"Poddubnyy D, Sieper J. Treatment of axial spondyloarthritis: What does the future hold? Curr Rheumatol Rep. 2020;22:47. https:\/\/doi.org\/10.1007\/s11926-020-00924-5.","journal-title":"Curr Rheumatol Rep"},{"key":"885_CR35","doi-asserted-by":"publisher","first-page":"107925","DOI":"10.1016\/j.pharmthera.2021.107925","volume":"229","author":"F Kolbinger","year":"2022","unstructured":"Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, McInnes IB, Ritchlin CT, Rosmarin D, Schett G, et al. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacol Ther. 2022;229:107925. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107925.","journal-title":"Pharmacol Ther"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00885-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00885-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00885-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:34:53Z","timestamp":1747658093000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00885-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["885"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00885-4","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Ethics Committee of the First Hospital of Jilin University (approval number: 20Y116-001) and conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice. Written informed consent was obtained from each participant before the study commenced.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}